BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24366192)

  • 1. Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm.
    Rampal R; Mascarenhas J
    Curr Opin Hematol; 2014 Mar; 21(2):65-71. PubMed ID: 24366192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.
    Tallarico M; Odenike O
    Curr Hematol Malig Rep; 2015 Jun; 10(2):112-7. PubMed ID: 25893311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.
    Li B; Mascarenhas JO; Rampal RK
    Curr Hematol Malig Rep; 2018 Dec; 13(6):588-595. PubMed ID: 30353413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
    Björkholm M; Hultcrantz M; Derolf ÅR
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic options for leukemic transformation in patients with myeloproliferative neoplasms.
    Khan M; Siddiqi R; Gangat N
    Leuk Res; 2017 Dec; 63():78-84. PubMed ID: 29121538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukemia secondary to myeloproliferative neoplasms.
    Dunbar AJ; Rampal RK; Levine R
    Blood; 2020 Jul; 136(1):61-70. PubMed ID: 32430500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemic transformation in patients with myeloproliferative neoplasms: a population-based retrospective study.
    Shrestha R; Giri S; Armitage JO; Bhatt VR
    Future Oncol; 2017 Jun; 13(14):1239-1246. PubMed ID: 28589759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
    Kundranda MN; Tibes R; Mesa RA
    Curr Hematol Malig Rep; 2012 Mar; 7(1):78-86. PubMed ID: 22170483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.
    Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S124-9. PubMed ID: 27521308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute Myeloid Leukemia and Other Types of Disease Progression in Myeloproliferative Neoplasms.
    Czader M; Orazi A
    Am J Clin Pathol; 2015 Aug; 144(2):188-206. PubMed ID: 26185305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated Phase of Myeloproliferative Neoplasms.
    Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
    Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics of myeloid malignancies: pathogenetic and clinical implications.
    Fröhling S; Scholl C; Gilliland DG; Levine RL
    J Clin Oncol; 2005 Sep; 23(26):6285-95. PubMed ID: 16155011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options.
    Iurlo A; Cattaneo D; Gianelli U
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.
    Yogarajah M; Tefferi A
    Mayo Clin Proc; 2017 Jul; 92(7):1118-1128. PubMed ID: 28688466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia.
    Malhotra J; Kremyanskaya M; Schorr E; Hoffman R; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):31-6. PubMed ID: 24220620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study.
    Hur JY; Choi N; Choi JH; Kim J; Won YW
    Thromb Res; 2024 Apr; 236():209-219. PubMed ID: 38461615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathology of myeloproliferative neoplasms.
    Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
    Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.
    Zhang SJ; Rampal R; Manshouri T; Patel J; Mensah N; Kayserian A; Hricik T; Heguy A; Hedvat C; Gönen M; Kantarjian H; Levine RL; Abdel-Wahab O; Verstovsek S
    Blood; 2012 May; 119(19):4480-5. PubMed ID: 22431577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
    Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
    Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.